Talent Strategy for Pre-Revenue Biotech: When to Hire vs. Contract

Why the Hire-vs-Contract Decision Matters Strategically

The hire-vs-contract decision in pre-revenue biotech is consequential for three reasons that go beyond the headline cash flow consideration.

The first reason is dilution. Full-time senior hires in biotech receive meaningful equity packages, typically 0.5 to 2.5 percent of the company for VP-level hires and higher for C-suite hires. Across a pre-Phase-2 biotech’s full-time hiring, the cumulative dilution from senior equity packages can exceed 15 percent of the company. Equivalent capability accessed through fractional or contracted arrangements typically costs equity in the 0.1 to 0.5 percent range or none at all. The dilution savings from disciplined contract-vs-hire decisions, compounded across multiple roles, can preserve five to ten percent of the company for the founding team and earlier investors.

The second reason is optionality. Full-time hires are difficult and expensive to unwind. Severance, equity acceleration, and the morale impact of executive departures are real costs that affect the company beyond the dollar amount of the severance check. Contracted arrangements provide optionality: the contract can be modified, extended, or terminated based on what the biotech learns about its needs. For pre-revenue biotechs where the strategic direction is still evolving, optionality has real value.

The third reason is access to pattern recognition. Fractional executives and senior contractors typically work with multiple biotechs simultaneously, exposing them to patterns across a portfolio of companies. A full-time hire sees one company in depth. A fractional executive sees five to ten companies in breadth. For pre-revenue biotechs facing strategic decisions where the right answer depends on having seen the analogous situation play out elsewhere, the pattern recognition of a fractional executive is often more valuable than the depth of a full-time hire.

These three reasons together mean that the decision should be made deliberately, not by default. The default in many biotechs is “if it’s senior and important, hire full-time.” That default is wrong as a general rule, and the biotechs that recognize it as wrong and make the decision deliberately preserve significant strategic and financial advantage over the biotechs that don’t. As industry analysis from BioSpace coverage of biotech talent strategy in 2025 has documented, the spread between well-managed and poorly-managed talent strategies in biotech is becoming a material driver of capital efficiency.

The Four Dimensions of the Decision

The hire-vs-contract decision is best made by evaluating four dimensions for the specific capability being considered.

Strategic depth required. Capabilities that require deep, organization-specific institutional knowledge favor hiring. Capabilities that are essentially portable across organizations favor contracting. Drug-specific clinical leadership for a novel mechanism requires depth that only a full-time hire can build. AI governance framework leadership, by contrast, is largely portable: the framework patterns are similar across companies, and a fractional CAIO can drop into multiple companies with comparable effectiveness.

Continuity requirement. Capabilities that require continuous presence and continuity favor hiring. Capabilities whose load is episodic favor contracting. A VP of Manufacturing for a biotech preparing for GMP scale-up requires continuous presence; the work is ongoing and the relationships with CMOs require ownership. A Chief AI Officer’s load, by contrast, is lumpy: high during platform setup and during major submissions, lower between inflection points. The lumpy load matches a fractional structure naturally.

IP and confidentiality risk. Capabilities that work with the company’s most sensitive IP favor hiring or carefully constructed contractor arrangements with strong confidentiality protections. Capabilities that operate primarily on the operating framework rather than the specific science have lower IP exposure. The decision is not absolute; senior contractors with strong reputations and explicit confidentiality agreements can work effectively with sensitive IP, but the decision should be made consciously.

Cash and equity cost. Pre-revenue biotechs operate on capital that has to last to the next funding milestone. The cash and equity cost of any capability needs to be evaluated against that runway, not against the abstract value of the capability. A full-time CAIO at $500K all-in plus 1 percent equity may provide more value than a fractional CAIO at $200K, but if the additional $300K and equity cost the biotech three months of runway, the trade-off may not favor the full-time hire even if the capability is greater.

These four dimensions are evaluated together. No single dimension is sufficient. Capabilities that score high on one dimension and low on others can go either way, and the deliberation is about which combination of trade-offs best fits the biotech’s specific situation.

Capability Types and Their Default Patterns

Across pre-revenue biotechs, certain capability types have emerged with recognizable default patterns. The defaults are not absolute, but they reflect what works for the typical biotech and provide a starting point for the deliberation.

Several patterns are notable. The CEO and CSO are always full-time; these are the roles where strategic depth and continuity are both binding constraints, and the dilution cost is justified. The CMO, CFO, regulatory, quality, manufacturing, and AI leadership roles are typically fractional or contracted at preclinical and Phase 1, with the transition to full-time hire happening at different points depending on the role.

The CMO transition to full-time typically happens as the clinical portfolio scales: when the biotech has more than one trial running, when the trials are pivotal rather than exploratory, or when the CMO’s load reaches near-full-time. The CFO transition typically happens at Series B preparation, when the financial complexity of the company exceeds what a fractional CFO can manage. The regulatory and quality transitions typically happen before IND filing, when the regulatory load becomes continuous. The AI leadership transition typically happens at Series C or later, when the AI portfolio’s scale justifies the full-time presence.

The Stage-Based Talent Architecture

A useful framing for biotech talent strategy is the stage-based architecture: thinking through what the talent stack should look like at each stage, rather than making the decisions one role at a time.

Seed stage (under 20 FTE). CEO and CSO full-time. Everything else fractional, contracted, or outside counsel. Total executive headcount is two; everything else is accessed through specialist arrangements. Cash burn from executive compensation is minimized to extend runway to Series A.

Series A (20-60 FTE). CEO, CSO, and typically a VP of Operations or Chief Operating Officer added as the company’s operational complexity grows. The remaining functions are still primarily fractional or contracted. The first scientific and operational mid-level hires (Director of Research, Director of Operations, Senior Scientist roles) come in to execute the science.

Series B (60-120 FTE). Full-time hires expand into CMO (as clinical scales), VP Regulatory (as IND approaches), and CFO (as financial complexity grows). Fractional arrangements continue for AI leadership, quality, manufacturing (until CMO scale-up), HR, and legal.

Series C and beyond (120+ FTE). The talent stack progressively fills out as functions reach the scale that justifies full-time executive presence. The biotech transitions from a fractional-heavy structure to a more traditional executive structure, but the transition is paced to actual organizational scale rather than to ambition.

The stage-based architecture is a default, not a prescription. Specific biotechs may move faster or slower depending on the scientific category, the capital position, and the strategic priorities. The framework’s value is in giving CEOs and boards a structured starting point that distinguishes between deliberate variation and unstructured drift.

Economics: Comparing the Real Costs

The economics of hire-vs-contract should be evaluated on total cost including equity, not just cash compensation. The framing that follows compares the typical alternatives for a VP-level role in biotech.

Full-time hire. Base salary of $280K to $400K depending on function and location. Bonus target of 20 to 30 percent of base. Equity of 0.4 to 1.0 percent of the company depending on stage and seniority. Benefits and overhead at approximately 30 percent of base. Total cash cost in year one of $400K to $650K depending on configuration, plus equity that may be worth substantially more depending on outcome.

Fractional executive. Cash fee of $120K to $250K depending on engagement intensity (one to two days per week). Equity of 0 to 0.5 percent in advisor shares or restricted stock. Benefits and overhead minimal because the engagement is external. Total cost in year one of $120K to $300K including modest equity.

Contracted specialist. Project-based or retainer-based engagement at $200 to $400 per hour, typically 200 to 600 hours per year. Total cost in year one of $40K to $240K depending on hours. No equity. No long-term commitment.

CRO or service provider. Per-project pricing varying by service. Highly variable; typical engagements for specific functions (regulatory submissions, validation activities, quality consulting) run $50K to $300K per project depending on scope.

The comparison is not just about cost. The full-time hire provides continuity, integration, and accountability that the alternatives do not match. The fractional executive provides pattern recognition and strategic depth that contracted specialists do not match. The contracted specialist provides flexibility and narrow expertise that fractional executives may not match. The CRO provides operational execution at scale that internal hires may not match.

The right framing for CEOs and boards is not “which option is cheapest” but “which combination of options best fits the capability load for the next 18 months.” A capability with high continuity requirement and moderate strategic depth may best fit a hire; a capability with episodic load and high strategic breadth may best fit a fractional executive; a capability with narrow technical scope and project-based timing may best fit a contracted specialist.

Failure Modes and How to Avoid Them

Five failure modes recur across pre-revenue biotech talent decisions.

Premature full-time hiring. Hiring full-time for capabilities whose actual load is episodic. The hire operates at low utilization, consumes cash and equity beyond what the load justifies, and becomes difficult to unwind when the load shifts. The fix is the discipline of asking whether the load is actually continuous before committing to a hire.

Excessive contract reliance. Relying on contractors and fractional executives for capabilities that genuinely require continuous internal presence. The contracted arrangements work for a period but break down when the capability load grows beyond what external arrangements can sustain, often at exactly the moment the biotech can least afford a leadership gap. The fix is the transition planning that anticipates when a fractional or contracted role needs to convert to a hire.

Title inflation in fractional arrangements. Engaging a fractional executive but treating them as a part-time individual contributor rather than a part-time executive. The result is that the fractional executive does not have the access, authority, or organizational integration to operate effectively, and the engagement underperforms. The fix is treating fractional arrangements as fractional executive arrangements, with the access and authority that implies.

Misaligned equity expectations. Offering equity at levels that signal a more strategic engagement than the actual arrangement, or undermarking equity for engagements that are functionally strategic. The fix is calibrating equity to actual scope: minimal advisor shares for genuinely advisory engagements, restricted stock at 0.1 to 0.5 percent for fractional executive engagements, full equity packages for full-time hires.

Failure to build internal capacity. Using fractional or contracted arrangements as a permanent substitute for building internal capability that the biotech will need at scale. The biotech reaches Series C without the internal team that should have been growing alongside the fractional leadership, and the transition to full-time leadership becomes a discontinuity rather than a graduation. The fix is using the fractional period to deliberately build the internal team that will support the eventual full-time hire.

Transition Signals: When to Convert Contract to Hire

The transition from contracted or fractional arrangement to full-time hire should be a deliberate decision triggered by recognizable signals. Three signals reliably indicate that the time is right.

The first signal is sustained load above 60 percent. When a fractional executive is operating at the equivalent of three or four days per week consistently across multiple months, the engagement has effectively become full-time and the structure should be formalized. The signal is not isolated busy weeks; it is sustained load above 60 percent across at least three consecutive months.

The second signal is regulatory or strategic continuity requirement. When the biotech’s regulatory load reaches the point where external regulators expect continuous, named, internal leadership (typically as IND filing approaches, or as pivotal trials begin), the conversion should happen before the regulatory engagement becomes intense. The cost of not having continuous internal leadership at this stage materially exceeds the cost of converting earlier.

The third signal is the development of the team beneath the role. When the function has grown to the point where the fractional executive is making decisions about hiring, performance, and team structure on a continuous basis, the function effectively requires full-time leadership presence. The biotech that delays the conversion at this point typically experiences team friction and turnover that costs more than the conversion would have cost.

The conversion conversation should happen explicitly with the fractional executive. In many cases, the fractional executive is the right candidate for the full-time role; the conversation is whether they are willing and able to convert. In other cases, the fractional executive prefers to remain fractional and the biotech needs to hire externally. Either way, the conversation should be planned, not deferred until the fractional arrangement visibly breaks. As research from PharmaVoice on biotech talent strategy has emphasized, the transition planning is itself a leadership discipline that separates well-managed biotechs from those that lurch from arrangement to arrangement reactively.

The strategic implication for biotech CEOs and boards is straightforward. The hire-vs-contract decision is made repeatedly across the company’s pre-revenue years, and the cumulative effect of making the decision well is substantial: preserved equity, extended runway, access to pattern recognition, and the strategic flexibility to adjust as the company learns. The cumulative effect of making the decision poorly is equally substantial: dilution that could have been avoided, cash burn that shortens runway, executive churn that disrupts continuity. The framework articulated in this article is not the only way to make the decision well, but it is a structured starting point that helps CEOs and boards make the decision deliberately rather than by default. The discipline is small at each individual decision; the cumulative effect over the pre-revenue years is large.

References & Sources